Comparison · NCT03066609-2491dceb
Secukinumab 150mg vs Secukinumab 300mg: Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Secukinumab 150mg vs Secukinumab 300mg: Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation). Trial comparisons, record NCT03066609-2491dceb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03066609-2491dceb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.839 | 0.76 | 0.896 | wilson | |
| Risk in group 2 | 0.925 | 0.886 | 0.952 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0859 | -0.169 | -0.0172 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.907 | 0.831 | 0.991 | log | |
| Odds ratio, group 1 over group 2 | 0.422 | 0.212 | 0.84 | log | |
| Number needed to treat, for one fewer participant with the outcome on Secukinumab 150mg than on Secukinumab 300mg | 11.6 | 5.91 | 58.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Secukinumab 150mg | Secukinumab 150mg s.c. | 94 | 112 | OG000 |
| Group 2 | Secukinumab 300mg | Secukinumab 300mg s.c. | 235 | 254 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)
- Description
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).
- Time frame
- Week 52
- Population
- full analysis set with measure
Source ClinicalTrials.gov
Trial
- Title
- Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
- NCT number
- NCT03066609
- Phases
- PHASE3
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c., Placebo
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-12-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03066609?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03066609-2491dceb